{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:48:56Z","timestamp":1785905336536,"version":"3.56.0"},"reference-count":82,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Proteins and associated post-translational modifications are receiving deserved attention in the search for immune therapies to combat a long list of diseases, including a number of fatal forms of cancer. Such attention has been fueled by a number of clinical results generated by numerous clinical trials, together with datasets generated by academic research. The title of this review is based on a couple of considerations: most, if not all, researched immune checkpoints are proteins, each of which can experience one or more post-translational modifications (PTMs). It is also known that among the main functions of post-translational modifications is their direct impact on protein localization. Given that most activities of known checkpoints are performed on the surface of the host cells, post-translational modifications are bound to influence the role of these proteins, both as drivers of various diseases and as therapeutic targets. The second consideration concerns another class of proteins, which is responsible for a severe toxic reaction in the immune system following treatment with immune cell inhibitors, a reaction known as cytokine release syndrome (CRS). Cytokines are low-molecular-weight proteins, among which the key members are interleukin-1 (IL-1), interleukin-6 (IL-6), and interferon \u03b3 (IFN-\u03b3). A number of clinical trials have shown that the symptoms of CRS toxicities are frequently accompanied by elevated levels of cytokines, including IL-6 and IFN-\u03b3. The recent literature suggests that we still need to know more about the biology of these proteins and the type of modifications that these key members of cytokines can experience. Such additional knowledge may contribute to more effective and safer immune cell therapy. The contribution of mass-spectrometry-based proteomics to the investigation of PTMs associated with immune checkpoints and cytokines is discussed.<\/jats:p>","DOI":"10.3390\/cancers18152471","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:02:01Z","timestamp":1785510121000},"page":"2471","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protein Glycosylation and Its Role in Current Immunotherapeutic Strategies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-1233","authenticated-orcid":false,"given":"Marco","family":"Agostini","sequence":"first","affiliation":[{"name":"Istituto di Ricerca Pediatrica Citt\u00e0 della Speranza, Corso Stati Uniti 4, 35100 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-3614","authenticated-orcid":false,"given":"Pietro","family":"Traldi","sequence":"additional","affiliation":[{"name":"Istituto di Ricerca Pediatrica Citt\u00e0 della Speranza, Corso Stati Uniti 4, 35100 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hamdan","sequence":"additional","affiliation":[{"name":"Istituto di Ricerca Pediatrica Citt\u00e0 della Speranza, Corso Stati Uniti 4, 35100 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1084564","article-title":"The Human Genome Project: Lessons from large-scale biology","volume":"300","author":"Collins","year":"2003","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Naryzhny, S. (2024). Puzzle of proteoform variety\u2014Where is a Key?. Proteomes, 12.","DOI":"10.3390\/proteomes12020015"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1002\/mco2.261","article-title":"Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications","volume":"4","author":"Zhong","year":"2023","journal-title":"MedComm"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2300178","DOI":"10.1002\/bies.202300178","article-title":"The logic of protein post-translational modifications (PTMs): Chemistry, mechanisms and evolution of protein regulation through covalent attachments","volume":"46","author":"Suskiewicz","year":"2024","journal-title":"BioEssays"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"141017","DOI":"10.1016\/j.bbapap.2024.141017","article-title":"Chemical proteomics approaches for protein post-translational modification studies","volume":"1872","author":"Zhang","year":"2024","journal-title":"Biochim. Biophys. Acta-Proteins Proteom."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41589-024-01805-z","article-title":"Mechanisms of metabolism-coupled protein modifications","volume":"21","author":"Zhang","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"118013","DOI":"10.1016\/j.bmc.2024.118013","article-title":"Investigation of protein post-translational modifications with site-specifically incorporated non-canonical amino acids","volume":"117","author":"Gu","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lens, M., and Schachter, J. (2025). Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data. Cancers, 17.","DOI":"10.3390\/cancers17111835"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hossain, S.M., Ly, K., Sung, Y.J., Braithwaite, A., and Li, K. (2024). Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251810120"},{"key":"ref_10","first-page":"1515","article-title":"Current status of management of immune-related adverse events and practical needs for oncologist education","volume":"22","author":"Tian","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1078-0432.CCR-25-3352","article-title":"When Checkpoint Inhibitors Break Barriers: Mechanisms and Challenges of irAEs of the Skin, Gastrointestinal Tract, and Lung","volume":"32","author":"Sinha","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","article-title":"The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis","volume":"27","author":"Wang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1\/PD-L1 Therapeutic Efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"120115","DOI":"10.1016\/j.bbamcr.2026.120115","article-title":"The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy","volume":"1873","author":"Gabriel","year":"2026","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1042\/BCJ20240769","article-title":"The biology of interleukin-6 family cytokines is regulated by glycosylation","volume":"482","author":"Kohrs","year":"2025","journal-title":"Biochem. J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Garcia-Robledo, J.E., Cabrera-Salcedo, S., Brandauer, A.M., Romano, F., Rengifo-Martinez, J., Toro-Pedroza, A., Sebasti\u00e1n Victoria, J., Rios-Serna, L.J., Loukanov, A., and Cardona, A.F. (2026). Engineering the next generation of CAR T- cells: Precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1698442"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sioud, M., and Casey, N.P. (2026). Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27020909"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.ymthe.2022.07.006","article-title":"Targeting glycans for CAR therapy: The advent of sweet CARs","volume":"30","author":"Raglow","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.tips.2025.07.013","article-title":"Targeting glycosylation to enhance tumor immunotherapy","volume":"46","author":"Zhu","year":"2025","journal-title":"Trends Pharm. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving gene-engineered T cell immunotherapy of cancer","volume":"27","author":"Johnson","year":"2017","journal-title":"Cell Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1038\/s41467-023-39828-0","article-title":"Detecting diagnostic features in MS\/MS spectra of post-translationally modified peptides","volume":"14","author":"Geiszler","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_24","first-page":"1208","article-title":"Investigating capillary electrophoresis-mass spectrometry for the analysis of common post-translational modifications","volume":"839","author":"Sarg","year":"2018","journal-title":"Electrophoresis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13024-017-0229-1","article-title":"A validated antibody panel for the characterization of tau post-translational modifications","volume":"12","author":"Ercan","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9528","DOI":"10.1073\/pnas.0402700101","article-title":"Peptide and Protein sequence analysis by electron transfer dissociation mass spectrometry","volume":"101","author":"Syka","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/ac990811p","article-title":"Electron capture dissociation for structural characterization of multiply charged protein cations","volume":"72","author":"Zubarev","year":"2000","journal-title":"Anal. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1021\/acs.chemrev.9b00440","article-title":"Ultraviolet Photodissociation Mass Spectrometry for Analysis of Biological Molecules","volume":"120","author":"Brodbelt","year":"2020","journal-title":"Chem. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1021\/ac061455v","article-title":"Fragmentation Characteristics of Collision-Induced Dissociation in MALDI TOF\/TOF Mass Spectrometry","volume":"79","author":"Khatun","year":"2007","journal-title":"Anal. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100881","DOI":"10.1016\/j.mcpro.2024.100881","article-title":"Integrative Multi-PTM Proteomics Reveals Dynamic Global, Redox, Phosphorylation, and Acetylation Regulation in Cytokine-Treated Pancreatic Beta Cells","volume":"23","author":"Gluth","year":"2024","journal-title":"Mol. Cell. Proteom."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100800","DOI":"10.1016\/j.mcpro.2024.100800","article-title":"Data-independent acquisition: A Milestone and prospect in clinical mass spectrometry\u2013based proteomics","volume":"23","author":"Fahrner","year":"2024","journal-title":"Mol. Cell. Proteom."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102622","DOI":"10.1016\/j.cbpa.2025.102622","article-title":"Mass spectrometry-based characterization of histone post-translational modification","volume":"88","author":"Zhao","year":"2025","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/febs.15707","article-title":"Mass spectrometry-based characterization of histones in clinical samples: Applications, progress, and challenges","volume":"289","author":"Noberini","year":"2022","journal-title":"FEBS J."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wei, D., Horton, K.L., Chen, J., Dong, L., Chen, S., Abdul-Hadi, K., Zhang, T.T., Casson, C.N., Shaw, M., and Shiraishi, T. (2023). Development of a highly sensitive hybrid LC\/MS assay for the quantitative measurement of CTLA-4 in human T Cells. Molecules, 28.","DOI":"10.3390\/molecules28083311"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2019.03.028","article-title":"The \u03b3c Family of Cytokines: Basic Biology to Therapeutic Ramifications","volume":"50","author":"Leonard","year":"2019","journal-title":"Immunity"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s40263-020-00766-w","article-title":"Overview of Current Drug Delivery Methods Across the Blood\u2014Brain Barrier for the Treatment of Primary Brain Tumors","volume":"34","author":"Haumann","year":"2020","journal-title":"CNS Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Slika, H., Shahani, A., Wahi, R., Miller, J., Groves, M., and Tyler, B. (2024). Overcoming Treatment Resistance in Medulloblastoma: Underlying Mechanisms and Potential Strategies. Cancers, 16.","DOI":"10.3390\/cancers16122249"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: Structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e003897","DOI":"10.1136\/jitc-2021-003897","article-title":"Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer","volume":"10","author":"Reppel","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","article-title":"Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15","volume":"25","author":"Chen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-023-00625-0","article-title":"Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma","volume":"10","author":"Lei","year":"2024","journal-title":"Cell Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41419-025-08405-2","article-title":"A new strategy for CAR-T therapy in solid tumors: IL-15-autocrine signaling augments tumor stroma depletion and promotes a TSCM subset in the TME","volume":"17","author":"Pang","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3-CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"D471","DOI":"10.1093\/nar\/gkab1017","article-title":"dbPTM in 2022: An Updated Database for Exploring Regulatory Networks and Functional Associations of Protein Post-Translational Modifications","volume":"50","author":"Li","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ridgeway, N.H., and Biggar, K.K. (2025). Uncovering Enzyme-Specific Post-Translational Modifications: An Overview of Current Methods. Proteomes, 13.","DOI":"10.3390\/proteomes13030037"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0003-9861(89)90427-X","article-title":"post-translational modifications of human interleukin-6","volume":"274","author":"Santhanam","year":"1989","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Laubli, H., and Borsig, L. (2019). Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02120"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41392-024-01886-1","article-title":"Glycosylation: Mechanisms, biological functions and clinical implications","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.3390\/v7102872","article-title":"Phosphorylation of single stranded RNA virus proteins and potential for novel therapeutic strategies","volume":"7","author":"Keck","year":"2015","journal-title":"Viruses"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"189274","DOI":"10.1016\/j.bbcan.2025.189274","article-title":"Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies","volume":"1880","author":"Granica","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1038\/s41467-025-58740-3","article-title":"Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity","volume":"16","author":"Huang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.tips.2025.08.008","article-title":"The B7-H3 (CD276) pathway: Emerging biology and clinical therapeutics","volume":"46","author":"Corrigan","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"217498","DOI":"10.1016\/j.canlet.2025.217498","article-title":"Regulation of PD-L1 glycosylation and advances in cancer immunotherapy","volume":"612","author":"Lee","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12943-025-02330-w","article-title":"N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1","volume":"24","author":"Kaufman","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12943-025-02397-5","article-title":"Post-translational modifications of cancer immune checkpoints: Mechanisms and therapeutic strategies","volume":"24","author":"Jia","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12929-025-01202-1","article-title":"Post-translational modifications of immune checkpoints: Molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications","volume":"33","author":"Hsieh","year":"2026","journal-title":"J. Biomed. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.7150\/jca.77619","article-title":"Clinical implications of the interaction between PD-1\/PD-L1 and PI3K\/AKT\/mTOR pathway in progression and treatment of non-small cell lung cancer","volume":"13","author":"Quan","year":"2022","journal-title":"J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-L\u00f3pez, A., Olaya-Vargas, A., Bustamante-Ogando, J.C., and Meneses-Acosta, A. (2025). Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases. Pharmaceuticals, 18.","DOI":"10.3390\/ph18020156"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41392-025-02219-6","article-title":"N-deglycosylation targeting chimera (DGlyTAC): A strategy for immune checkpoint proteins inactivation by specifically removing N-glycan","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/bs.acc.2018.12.005","article-title":"Glycosylation markers in cancer","volume":"89","author":"Silsirivanit","year":"2019","journal-title":"Adv. Clin. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/cac2.12610","article-title":"Altered glycosylation in cancer: Molecular functions and therapeutic potential","volume":"44","author":"Xu","year":"2024","journal-title":"Cancer Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1186\/s12967-024-05502-2","article-title":"N-linked glycosylation of PD-L1\/PD-1: An emerging target for cancer diagnosis and treatment","volume":"22","author":"Duan","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e202302368","DOI":"10.26508\/lsa.202302368","article-title":"Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors","volume":"7","author":"Chu","year":"2024","journal-title":"Life Sci. Alliance"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/1535370219855970","article-title":"Considering B7-CD28 as a family through sequence and structure","volume":"244","author":"West","year":"2019","journal-title":"Exp. Biol. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41467-021-22618-x","article-title":"FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1038\/s41401-023-01118-2","article-title":"Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities","volume":"44","author":"Li","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s40364-025-00872-1","article-title":"Development of a bispecific antibody that inhibits EGFR and B7H3 in NSCLC","volume":"13","author":"Zhi","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.36401\/JIPO-23-18","article-title":"B7-H3 Inhibitors in Oncology Clinical Trials: A Review","volume":"7","author":"Feustel","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Mielcarska, S., Kot, A., Dawidowicz, M., Kula, A., Sobk\u00f3w, P., K\u0142aczka, D., Waniczek, D., and \u015awi\u0119tochowska, D. (2025). B7-H3 in Cancer Immunotherapy\u2014Prospects and Challenges: A Review of the Literature. Cells, 14.","DOI":"10.3390\/cells14151209"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"102117","DOI":"10.1016\/j.xcrm.2025.102117","article-title":"Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses","volume":"6","author":"Lin","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12014-025-09525-9","article-title":"Integrated proteomics and N-glycoproteomic characterization of glioblastoma multiform revealed N-glycosylation heterogeneities as well as alterations in sialyation and fucosylation","volume":"22","author":"Hu","year":"2025","journal-title":"Clin. Proteom."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3724\/abbs.2024107","article-title":"Glycosylation in the tumor immune response: The bitter side of sweetness","volume":"56","author":"Cao","year":"2024","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.cr.7290243","article-title":"The expression of core fucosylated E-cadherin in cancer cells and lung cancer patients: Prognostic implications","volume":"14","author":"Geng","year":"2004","journal-title":"Cell Res."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Lin, J., Xu, W., Xia, L., Zhang, C., Ge, L., Gao, J., Bao, J., Xu, Y., Sun, X., and Li, H. (2025). A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: Focus on non-small cell lung cancer. BMC Pulm. Med., 25.","DOI":"10.1186\/s12890-025-03944-y"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e0422","DOI":"10.1097\/HC9.0000000000000422","article-title":"Alpha-fetoprotein: Past, present, and future","volume":"8","author":"Yeo","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_79","first-page":"81","article-title":"Biomarkers for Early Detection of Ovarian Cancer","volume":"9","author":"Teja","year":"2023","journal-title":"Asian Pac. J. Cancer Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"100986","DOI":"10.1016\/j.medj.2025.100986","article-title":"Advances and perspectives in CEA-targeted therapies: From classic biomarker toward actionable therapeutic target","volume":"7","author":"Sun","year":"2026","journal-title":"Med"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100305","DOI":"10.1016\/j.jlb.2025.100305","article-title":"Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions","volume":"9","author":"Crocetto","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41420-019-0164-8","article-title":"Core fucosylated glycan-dependent inhibitory effect of QSOX1-S on invasion and metastasis of hepatocellular carcinoma","volume":"5","author":"Zhang","year":"2019","journal-title":"Cell Death Discov."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2471\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:20:25Z","timestamp":1785903625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":82,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152471"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152471","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]}}}